Expression Levels of Tetraspanin KAI1/CD82 in Breast Cancers in North Indian Females

  • Singh, Richa (Department of Radiotherapy, King George's Medical University) ;
  • Bhatt, Madan Lal Brahma (Department of Radiotherapy, King George's Medical University) ;
  • Singh, Saurabh Pratap (Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences) ;
  • Kumar, Vijay (Department of Surgical Oncology, King George's Medical University) ;
  • Goel, Madhu Mati (Department of Pathology, King George's Medical University) ;
  • Mishra, Durga Prasad (Endocrinology Division, Central Drug Research Institute (CSIR)) ;
  • Srivastava, Kirti (Department of Radiotherapy, King George's Medical University) ;
  • Kumar, Rajendra (Department of Radiotherapy, King George's Medical University)
  • Published : 2016.07.01


Background: Carcinogenesis is a multifaceted intricate cellular mechanism of transformation of the normal functions of a cell into neoplastic alterations. Metastasis may result in failure of conventional treatment and death Hence, research on metastatic suppressors in cancer is a high priority. The metastatic suppressor gene CD82, also known as KAI1, is a member of the transmembrane 4 superfamily which was first identified in carcinoma of prostate. Little work has been done on this gene in breast cancer. Herein, we aimed to determine the gene and protein level expression of CD82/KAI1 in breast cancer and its role as a prognosticator. Materials and Methods: In this study, 83 histologically proven cases of breast cancer and a similar number of controls were included. Patient age ranged from 18-70 years. Quantitative Real Time Polymerase Chain Reaction (q-RT PCR) and immunohistochemistry (IHC) were used to investigate KAI1 expression at gene and protein levels, respectively. Statistical analysis was done to correlate expression of KAI1 and clinicopathological parameters. Results: It was revealed that: (i) KAI1 was remarkably diminished in metastatic vs non metastatic breast cancer both at the gene and the protein levels (P < .05); (ii) KAI1 expression levels were strongly correlated with TNM staging, histological grade and advanced stage (p<0.001) and no association was found with any other studied parameter; (iii) Lastly, a significant correlation was observed between expression of KAI1 and overall median survival of BC patients (P = 0.04). Conclusions: Our results suggest that lack of expression of the KAI1 might indicate a more aggressive form of breast cancer. Loss of KAI1 may be considered a significant prognostic marker in predicting metastatic manifestation. When evaluated along with the clinical and pathological factors, KAI1 expression may be beneficial to tailor aggressive therapeutic strategies for such patients.


  1. Adachi M, Taki T, Ieki Y, et al (1996). Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res, 56, 1751-5
  2. Adachi M, Taki T, Konishi T, et al (1998). Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol, 16, 1397-406
  3. Asthana S, Chauhan S, Labani S (2014). Breast and cervical cancer risk in India: an update. Indian J Public Health, 58, 5-10
  4. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA (1993). Molecular aspects of tumor cell invasion and metastasis. Cancer, 71, 1368-83<1368::AID-CNCR2820710432>3.0.CO;2-L
  5. Benjamin H. Beck, Danny R. Welch (2010). The KISS1 metastasis suppressor: A good night kiss for disseminated cancer cells. Eur J Cancer, 46, 1283-9.
  6. Bevilacqua JL, Kattan MW, Fey JV, et al (2007). Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol, 25, 3670-79.
  7. Brown CJ, Lain S, Verma CS, et al (2009). Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer, 9, 862-73.
  8. DeSantis C, Ma J, Bryan L, et al (2013). Breast cancer statistics, 2013. CA Cancer J Clin, 64, 52-62.
  9. Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P (2014). Breast cancer statistics and markers. J Cancer Res Ther, 10, 506-11.
  10. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al (1995). KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science, 268, 884-6.
  11. Friess H, Guo X Z, Berberat P, et al (1998). Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int J Cancer (Pred. Oncol.), 79, 349-55<349::AID-IJC7>3.0.CO;2-V
  12. Guo J, Fan Kx, Xie Li et al, (2015). Effect and prognostic significance of the KAI1 gene in human gastric carcinoma. Oncol Lett, 10, 2035-42
  13. Guo XZ, Friess H, Di Mola FF, et al (1998). KAI1. A new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma. Hepatol, 28, 1481-8
  14. Huang W, Yang J, Ren J, et al (2016). Expression of PTEN and KAI1 tumor suppressor genes in pancreatic carcinoma and its association with different pathological factors. Oncol Lett, 11, 559-62
  15. Kim JH, Kim B, Cai L, et al (2005). Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature, 434, 921-6
  16. Lazo PA (2007). Functional implications of tetraspanin proteins in cancer biology. Cancer Sci, 98, 1666-77
  17. Liu FS, Chen JT, Dong JT, et al (2001). KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma. Am J Pathol, 159, 1629-34
  18. Liu FS, Dong JT, Chen JT, et al (2000). Frequent downregulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecol Oncol, 78, 10-15
  19. Liu FS, Dong JT, Chen JT, (2003). KAI1 metastasis suppressor protein is down-regulated during the progression of human endometrial cancer. Clin Cancer Res, 9, 1393- 8
  20. Lombardi DP, Geradts J, Foley JF, et al (1999). Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res, 59, 5724-31
  21. Malik FA, Sanders AJ, Jones AD (2009) Transcriptional and translational modulation of KAI1 expression of KAI1 expression in ductal carcinoma of the breast and the prognostic significance the breast and the prognostic significance. Int J Mol Med, 23, 273-8
  22. Miyazaki T, Kato H, Shitara Y, et al (2000). Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer (Phila.), 89, 955-62<955::AID-CNCR3>3.0.CO;2-Z
  23. O'Shaughnessy J (2005). Extending Survival with Chemotherapy in Metastatic Breast Cancer. Oncologist, 10, 20-9
  24. Pan F, Mao H, Deng L et al, (2014). Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. Int J Clin Exp Pathol, 7, 5622-33
  25. Sato T, Tanigami A, Yamakawa K, et al (1990). Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res, 50, 7814-9
  26. Soerjomataram I, Louwman MW, Ribot JG, et al (2008). An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat, 107, 309-30
  27. Wright MD, et al (1994). The ins and outs of the transmembrane 4 superfamily. Immunol. Today, 15, 588-594
  28. Yang X, Wei L, Tang C, et al (2000). KAI1 protein is downregulated during the progression of human breast cancer. Clin Cancer Res, 6, 3424-9
  29. Yip CH, Rhodes A (2014). Estrogen and progesterone receptors in breast cancer. Future Oncol, 10, 2293-301
  30. Zhou XL, Wang M (2015). Expression levels of survivin, Bcl-2 and KAI1 proteins in cervical cancer and their correlation with metastasis. Genet Mol Res, 14, 17059-67